PHP
MBIO icon

Parkman Healthcare Partners’s Mustang Bio MBIO Stock Holding History

Parkman Healthcare Partners’s Portfolio MBIO Stock Details MBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-405
Closed -$965K – 91
2020
Q2 		$965K Hold
405
– – 0.27% 69
2020
Q1 		$813K Buy
405
+2
+0.5% +$5.13K 0.38% 58
2019
Q4 		$1.23M Buy
+403
New +$923K 0.36% 60

Other funds holding MBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Parkman Healthcare Partners's MBIO Position: Q3 2020 in Review

Parkman Healthcare Partners sold out of Mustang Bio (MBIO) in Q3 2020, closing a stake of 405 shares — an estimated $965K sold.

Parkman Healthcare Partners first reported a position in MBIO in Q4 2019 and held it in 3 quarters. The position peaked at $1.23M in Q4 2019. 75 funds tracked by Wall St. Rank hold MBIO as of Q3 2020.

  • Parkman Healthcare Partners reported no remaining Mustang Bio position as of Q3 2020 after selling out during the quarter.
  • Parkman Healthcare Partners sold 405 Mustang Bio shares in Q3 2020, an estimated $965K.
  • Parkman Healthcare Partners first reported a position in Mustang Bio in Q4 2019 and held it in 3 quarters.
  • Parkman Healthcare Partners's Mustang Bio position peaked at $1.23M in Q4 2019.
  • 75 funds tracked by Wall St. Rank held Mustang Bio as of Q3 2020.

Based on Parkman Healthcare Partners's 13F filing for Q3 2020, filed 13 Nov 2020.